Inotiv, Inc. (NOTV) - Dilution Analysis

10-Q filing | 34.7M shares outstanding

10-K filing | 32.5M shares outstanding

S-3 filing: Inotiv, Inc. is offering common shares with an aggregate offering price of up to $50.0 million through an at-the-market offering via Jefferies, with net proceeds intended for working capital and general corporate purposes.

10-Q filing | 34.4M shares outstanding

10-Q filing | 34.0M shares outstanding

10-Q filing | 33.9M shares outstanding

8-K filing: Inotiv, Inc. entered into an underwriting agreement for a public offering of 6,000,000 common shares at $4.25 per share, with an option for the underwriter to purchase an additional 900,000 shares. ($25.5M proceeds)

10-K filing | 25.9M shares outstanding

S-3 filing: This is an S-3 filing that discusses warrants, equity incentive plans, and convertible senior notes.

8-K filing: Inotiv, Inc. issued $22.0 million in Senior Secured Second Lien PIK Notes and warrants to purchase 3,946,250 common shares to certain investors, and $0.6 million in notes and warrants to purchase 200,000 common shares to a structuring agent, in exchange for cash and cancellation of existing convertible notes.

10-Q filing | 26.0M shares outstanding

10-Q filing | 25.8M shares outstanding

10-Q filing | 25.8M shares outstanding

10-K filing | 25.6M shares outstanding

10-Q filing | 25.7M shares outstanding

10-Q filing | 25.7M shares outstanding

10-Q filing | 25.6M shares outstanding

10-K filing | 24.4M shares outstanding

S-3/A filing: This is an S-3/A filing to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act. The registrant amends the registration statement to delay its effective date.

S-3 filing: The filing is an S-3 shelf registration for multiple types of securities up to $350 million and includes an offering of 6,964,728 common shares by selling shareholders.

10-Q filing | 15.9M shares outstanding

RW filing: The Registrant has determined not to pursue the public offering and withdraws the Registration Statement.

10-Q filing | 25.3M shares outstanding

10-Q filing | 24.3M shares outstanding

8-K filing: Inotiv, Inc. acquired Orient BioResource Center, Inc. for $28.2 million in cash and 677,339 shares of Inotiv's common stock and also amended its credit agreement to increase the term loan facility by $40.0 million and establish a new $35.0 million delayed draw term loan facility.

8-K filing: Inotiv, Inc. acquired Integrated Laboratory Systems, LLC for $38.8 million in cash and 429,118 shares of Inotiv's common stock.

S-1 filing: S-1 filing for offering of common shares.

10-K filing | 15.9M shares outstanding

8-K filing: Inotiv, Inc. completed the acquisition of Envigo RMS Holding Corp. on November 5, 2021, issuing 8,245,918 common shares to Envigo stockholders and increasing the number of authorized common shares from 19,000,000 to 74,000,000.

8-K filing: Joseph E. Flynn, former Chief Commercial Officer of Inotiv, Inc., terminated his employment on September 8, 2021, and entered into a Separation and Release Agreement on September 27, 2021, where he will forfeit unvested stock options and restricted stock awards and will be entitled to exercise 7,000 outstanding stock options until October 8, 2021.

8-K filing: Inotiv, Inc. entered into a definitive agreement to acquire Envigo RMS Holding Corp. through a merger involving cash consideration of $200 million and 9,365,173 Inotiv common shares. ($285.0M proceeds)

10-Q filing | 14.7M shares outstanding

10-Q filing | 15.8M shares outstanding

8-K filing: The Company issued 1,588,235 common shares to the Selling Shareholders at the Closing, relying on the exemption provided by Section 4(a)(2) of the Securities Act.

8-K filing: Inotiv, Inc. announced a public offering of 2,647,059 common shares at $17.00 per share, with net proceeds of approximately $42.5 million, to finance acquisitions and for general corporate purposes, with the offering expected to close on or about April 23, 2021. ($45.0M proceeds)

8-K filing: Inotiv, Inc. entered into an Asset Purchase Agreement with HistoTox Labs, Inc. to acquire substantially all of its assets and an Agreement and Plan of Merger with Bolder BioPATH, Inc. ($27.0M proceeds)

S-3 filing: The filing is an S-3 form registering an indeterminate amount of common shares, preferred shares, warrants, and/or units for sale, with an aggregate offering price not to exceed $100,000,000.

10-Q filing | 10.7M shares outstanding

10-K filing | 10.4M shares outstanding

10-Q filing | 10.3M shares outstanding

10-Q filing | 10.3M shares outstanding

10-Q filing | 10.8M shares outstanding